Platelet aggregation and quality control of platelet concentrates produced in the Amazon Blood Bank.

Maria José Dantas Coêlho, Taysa de Castro Monteiro, Felicien Gonçalves Vasquez, Kátia Luz Torres Silva, Kleber Sandro Brasil Dos Santos, Viviana Maria Araújo de Oliveira, Francimary de Oliveira Cavalcante
Author Information
  1. Maria José Dantas Coêlho: Blood Cycle Department, Laboratório de Fracionamento, Fundação de Hematologia e Hemoterapia do Amazonas, Manaus, AM, Brazil.

Abstract

BACKGROUND: The study of platelet aggregation is essential to assess in vitro platelet function by different platelet activation pathways.
OBJECTIVE: To assess aggregation and biochemical parameters of random platelet concentrates produced at the Fundação HEMOAM using the quality control tests defined by law.
METHODS: Whole blood samples from 80 donors and the respective platelet concentrate units were tested. Platelet concentrates were tested (platelet count, aggregation and pH) on days 1, 3 and 5 of storage. Additionally a leukocyte count was done only on day 1 and microbiological tests on day 5 of storage. Collagen and adenosine diphosphate were used as inducing agonists for platelet aggregation testing.
RESULTS: Donor whole blood had normal aggregation (aggregation with adenosine diphosphate = 67% and with collagen = 78%). The median aggregation in platelet concentrates with adenosine diphosphate was low throughout storage (18% on day 1, 7% on day 3 and 6% on day 5) and the median aggregation with collagen was normal only on day 1 and low thereafter (54.4% on day 1, 20.5% on day 3 and 9% on day 5).
CONCLUSION: Although the results were within the norms required by law, platelet concentrates had low aggregation rates. We suggest the inclusion of a functional assessment test for the quality control of platelet concentrates for a more effective response to platelet replacement therapy.

Keywords

References

  1. J Thromb Haemost. 2005 Aug;3(8):1717-24 [PMID: 16102038]
  2. Semin Thromb Hemost. 2009 Mar;35(2):139-49 [PMID: 19408187]
  3. Semin Hematol. 2010 Jul;47(3):220-6 [PMID: 20620432]
  4. Transfus Apher Sci. 2009 Oct;41(2):97-104 [PMID: 19699153]
  5. Transfusion. 2007 Oct;47(10):1889-95 [PMID: 17880616]
  6. Platelets. 2001 Sep;12(6):333-42 [PMID: 11672472]
  7. Platelets. 2008 Sep;19(6):440-6 [PMID: 18925512]
  8. Arterioscler Thromb Vasc Biol. 2003 Jul 1;23(7):1152-60 [PMID: 12738684]
  9. Pathophysiol Haemost Thromb. 2002;32 Suppl 1:47-52 [PMID: 12214148]
  10. Platelets. 2003 Jun;14(4):219-24 [PMID: 12850830]
  11. Clin Chem Lab Med. 2008;46(7):919-25 [PMID: 18605950]
  12. Transfusion. 2008 Jan;48(1):129-35 [PMID: 17894788]
  13. Transfus Apher Sci. 2009 Oct;41(2):139-44 [PMID: 19744888]
  14. Transfus Med. 2003 Aug;13(4):173-87 [PMID: 12880388]
  15. Vox Sang. 2005 Apr;88(3):153-63 [PMID: 15787725]
  16. J Physiol. 1963 Aug;168:178-95 [PMID: 14056485]
  17. J Thromb Haemost. 2005 Jul;3(7):1459-66 [PMID: 15978103]
  18. Transfus Sci. 2000 Feb-Apr;22(1-2):85-8 [PMID: 10771393]
  19. IUBMB Life. 2004 Jan;56(1):13-8 [PMID: 14992375]
  20. Transfusion. 2004 Jun;44(6):891-9 [PMID: 15157257]
  21. Semin Thromb Hemost. 2004 Aug;30(4):441-50 [PMID: 15354265]

Word Cloud

Created with Highcharts 10.0.0plateletaggregationdayconcentrates1control5qualityPlatelet3storageadenosinediphosphatelowBloodassessproducedtestslawbloodtestedcountCollagennormal=collagenmedianBACKGROUND:studyessentialvitrofunctiondifferentactivationpathwaysOBJECTIVE:biochemicalparametersrandomFundaçãoHEMOAMusingdefinedMETHODS:Wholesamples80donorsrespectiveconcentrateunitspHdaysAdditionallyleukocytedonemicrobiologicalusedinducingagoniststestingRESULTS:Donorwhole67%78%throughout18%7%6%thereafter544%205%9%CONCLUSION:AlthoughresultswithinnormsrequiredratessuggestinclusionfunctionalassessmenttesteffectiveresponsereplacementtherapyAmazonBankbankscomponenttransfusionHemostasisQuality

Similar Articles

Cited By